股本结构
单位：万股
| 公告日期 | 2026-08-10 | 2026-08-10 | 2026-05-12 | 2026-05-12 | 2026-03-19 | 2026-03-19 |
|---|---|---|---|---|---|---|
| 证券总股本 | 6173.55 | 6173.46 | 6155.32 | 6030.32 | 6030.32 | 159.73 |
| 普通股本 | 6173.55 | 6173.46 | 6155.32 | 6030.32 | 6030.32 | 159.73 |
| 优先股 | 未披露 | 1.81 | 未披露 | 1.84 | 1.82 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-07 | 2026-06-30 | 2026-05-11 | 2026-03-31 | 2026-03-17 | 2025-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-10 | 6173.55 | 未披露 | 定期报告 | 2026-08-07 |
| 2026-08-10 | 6173.46 | 1.81 |
更多>>
From March 31,2026 to June 30,2026
Conversion of Series A preferred shares to Common Stock
Exercise of stock options
Issuance of common stock in connection with vesting of restricted stock units
Proceeds from At-the-Market facility
|
2026-06-30 |
| 2026-05-12 | 6155.32 | 未披露 | 定期报告 | 2026-05-11 |
| 2026-05-12 | 6030.32 | 1.84 |
更多>>
From December 31,2025 to March 31,2026
Exercise of stock options
Issuance of common stock in connection with vesting of restricted stock units
Forfeiture of shares
Issuance of common stock in connection with offering, net of issuance costs of $20,753
|
2026-03-31 |
| 2026-03-19 | 6030.32 | 1.82 | 定期报告 | 2026-03-17 |
| 2026-02-11 | 6024.01 | 未披露 |
更多>>
Common Stock offered 14,473,685 shares by the company
The underwriters exercised their option to purchase common stock 2,171,052 shares
|
2026-02-12 |
| 2026-02-10 | 4359.53 | 1.82 | 定期报告 | 2026-02-09 |
| 2026-03-19 | 159.73 | 6.04 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of Series B and C non-voting convertible preferred and common stock in connection with the asset acquisition of Damora Therapeutics, Inc.
Issuance of Series C non-voting convertible preferred stock in connection with private placement, net of issuance costs
Issuance of preferred and common stock in connection with an Asset Purchase Agreement
Issuance of common stock in connection with vesting of restricted stock units
Exercise of stock options
|
2025-12-31 |
| 2025-12-31 | 159.73 | 未披露 | 定期报告 | 2025-12-29 |
| 2025-12-31 | 159.52 | 6.04 | 定期报告 | 2025-12-01 |
| 2025-11-06 | 132.72 | 0.02 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with vesting of restricted stock units
|
2025-09-30 |
| 2025-08-05 | 132.46 | 0.02 |
更多>>
From March 31, 2025 to June 30, 2025
Conversion of Series A Preferred Stock
|
2025-06-30 |
| 2025-05-08 | 132.24 | 0.02 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
|
2025-03-31 |
| 2025-03-19 | 132.24 | 未披露 | 定期报告 | 2025-03-03 |
| 2025-03-19 | 131.70 | 0.02 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of preferred and common stock in connection with an Asset Purchase Agreement
Round-up shares from the 1-for-25 reverse split effective August 29, 2024
Issuance of common stock in connection with vesting of restricted stock units
|
2024-12-31 |
| 2024-11-01 | 131.70 | 未披露 | 定期报告 | 2024-10-30 |
| 2024-10-07 | 131.09 | 0.02 |
更多>>
On October 7, 2024 the company issued 62,594 common shares and 160.562 Series A non-voting convertible preferred stock
|
2024-10-07 |
| 2024-11-01 | 125.38 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with vesting of restricted stock units
Round-up shares from the 1-for-25 reverse split effective August 29, 2024
|
2024-09-30 |
| 2024-09-11 | 124.83 | 未披露 | 定期报告 | 2024-09-10 |
| 2024-08-29 | 110.00 | 未披露 |
更多>>
a 1-for-25 Reverse Stock Split of its common stock
|
2024-08-30 |
| 2024-08-29 | 2710.00 | 未披露 | 定期报告 | 2024-08-28 |
| 2024-08-12 | 2713.02 | 未披露 | 定期报告 | 2024-08-07 |
| 2024-08-12 | 2712.10 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with vesting of restricted stock units
|
2024-06-30 |
| 2023-11-06 | 2711.27 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock; net of issuance costs of $0.1 million
|
2023-09-30 |
| 2023-07-31 | 2711.27 | 未披露 | 定期报告 | 2023-07-26 |
| 2023-07-31 | 2702.19 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock; net of issuance costs of $0.1 million
|
2023-06-30 |
| 2023-04-28 | 2567.35 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock; net of issuance costs
|
2023-03-31 |
| 2023-03-09 | 2567.35 | 未披露 | 定期报告 | 2023-03-06 |
| 2023-03-09 | 2565.24 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock; net of issuance costs of $0.2 million
|
2022-12-31 |
| 2022-11-08 | 2558.10 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock; net of issuance costs
|
2022-09-30 |
| 2022-07-29 | 2539.57 | 未披露 | 定期报告 | 2022-07-27 |
| 2022-07-29 | 2534.21 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock; net of issuance costs of $0.1 million
|
2022-06-30 |
| 2021-03-29 | 2526.18 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Conversion of convertible preferred stock into common stock
Issuance of Series D preferred stock, net of issuance costs of $2,840
Issuance of common stock in connection with initial public offering, net of issuance costs of $2,114
Exercise of stock options
|
2020-12-31 |
| 2020-12-11 | 2526.08 | 未披露 | 定期报告 | 2020-12-10 |
| 2020-10-30 | 2458.53 | 未披露 |
更多>>
1.Common stock offered by the company 5,666,667 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 259,966 shares of common stock outstanding as of June 30, 2020
|
2020-10-29 |
From March 31,2026 to June 30,2026
Conversion of Series A preferred shares to Common Stock
Exercise of stock options
Issuance of common stock in connection with vesting of restricted stock units
Proceeds from At-the-Market facility
From December 31,2025 to March 31,2026
Exercise of stock options
Issuance of common stock in connection with vesting of restricted stock units
Forfeiture of shares
Issuance of common stock in connection with offering, net of issuance costs of $20,753
Common Stock offered 14,473,685 shares by the company
The underwriters exercised their option to purchase common stock 2,171,052 shares
From December 31, 2024 to December 31, 2025
Issuance of Series B and C non-voting convertible preferred and common stock in connection with the asset acquisition of Damora Therapeutics, Inc.
Issuance of Series C non-voting convertible preferred stock in connection with private placement, net of issuance costs
Issuance of preferred and common stock in connection with an Asset Purchase Agreement
Issuance of common stock in connection with vesting of restricted stock units
Exercise of stock options
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with vesting of restricted stock units
From March 31, 2025 to June 30, 2025
Conversion of Series A Preferred Stock
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2023 to December 31, 2024
Issuance of preferred and common stock in connection with an Asset Purchase Agreement
Round-up shares from the 1-for-25 reverse split effective August 29, 2024
Issuance of common stock in connection with vesting of restricted stock units
On October 7, 2024 the company issued 62,594 common shares and 160.562 Series A non-voting convertible preferred stock
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with vesting of restricted stock units
Round-up shares from the 1-for-25 reverse split effective August 29, 2024
a 1-for-25 Reverse Stock Split of its common stock
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with vesting of restricted stock units
From June 30, 2023 to September 30, 2023
Issuance of common stock; net of issuance costs of $0.1 million
From March 31, 2023 to June 30, 2023
Issuance of common stock; net of issuance costs of $0.1 million
From December 31, 2022 to March 31, 2023
Issuance of common stock; net of issuance costs
From December 31, 2021 to December 31, 2022
Issuance of common stock; net of issuance costs of $0.2 million
From June 30, 2022 to September 30, 2022
Issuance of common stock; net of issuance costs
From March 31, 2022 to June 30, 2022
Issuance of common stock; net of issuance costs of $0.1 million
from December 31, 2019 to December 31, 2020
Conversion of convertible preferred stock into common stock
Issuance of Series D preferred stock, net of issuance costs of $2,840
Issuance of common stock in connection with initial public offering, net of issuance costs of $2,114
Exercise of stock options
1.Common stock offered by the company 5,666,667 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 259,966 shares of common stock outstanding as of June 30, 2020